Dermira Inc (NASDAQ:DERM) Director William R. Ringo sold 500 shares of Dermira stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $34.03, for a total value of $17,015.00. Following the transaction, the director now directly owns 500 shares in the company, valued at $17,015. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Dermira Inc (NASDAQ:DERM) traded down 2.87% on Friday, reaching $32.50. The company had a trading volume of 122,336 shares. The stock’s market capitalization is $1.16 billion. Dermira Inc has a 1-year low of $23.33 and a 1-year high of $38.75. The stock’s 50 day moving average is $34.83 and its 200-day moving average is $32.39.
Dermira (NASDAQ:DERM) last posted its earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.93) by $0.72. The firm earned $22.47 million during the quarter. On average, equities analysts predict that Dermira Inc will post ($3.70) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.chaffeybreeze.com/2017/04/21/dermira-inc-derm-director-sells-17015-00-in-stock-updated.html.
Several hedge funds have recently bought and sold shares of DERM. Great Point Partners LLC purchased a new stake in Dermira during the third quarter valued at $22,977,000. FMR LLC increased its stake in Dermira by 10.1% in the fourth quarter. FMR LLC now owns 4,710,737 shares of the biopharmaceutical company’s stock valued at $142,877,000 after buying an additional 433,601 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in Dermira during the third quarter valued at $11,040,000. Perceptive Advisors LLC purchased a new stake in Dermira during the fourth quarter valued at $9,875,000. Finally, Blue Jay Capital Management LLC purchased a new stake in Dermira during the third quarter valued at $9,301,000. 84.92% of the stock is owned by institutional investors and hedge funds.
A number of research analysts have recently weighed in on the company. SEB Equity Research reaffirmed a “reduce” rating on shares of Dermira in a research report on Tuesday, January 3rd. Mizuho assumed coverage on Dermira in a research report on Thursday, March 30th. They set a “buy” rating and a $42.00 price objective on the stock. Raymond James Financial, Inc. assumed coverage on Dermira in a research report on Thursday, March 16th. They set an “underperform” rating on the stock. Citigroup Inc assumed coverage on Dermira in a research report on Wednesday, March 15th. They set an “underperform” rating on the stock. They noted that the move was a valuation call. Finally, Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, January 10th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $44.20.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.